首页 社会内容详情
allbet欧博真人客户端:Sanofi ends cancer drug trials

allbet欧博真人客户端:Sanofi ends cancer drug trials

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

allbet欧博真人客户端www.aLLbet8.vip}是欧博集团的官方网站。欧博官网开放Allbet注册、Allbe代理、Allbet电脑客户端、Allbet手机版下载等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

Telegram营销www.tel8.vip)是一个Telegram群组分享平台。Telegram营销包括Telegram营销、Telegram群组索引、Telegram群组导航、新加坡Telegram群组、Telegram中文群组、Telegram群组(其他)、Telegram 美国 群组、Telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram营销为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
  • 皇冠代理网址(www.hg9988.vip) @回复Ta

    2022-09-12 00:51:40 

    THE parliamentary Public Accounts Committee (PAC) is independent and should not be used as political mileage by politicians, its chairman Wong Koh Woh said.满分给你,努力啊

发布评论